Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era | Zendy

Sanghee Hong | Zendy; Lisa Rybicki | Zendy; Donna Corrigan | Zendy; Betty K. Hamilton | Zendy; Ronald Sobecks | Zendy; Matt Kalaycio | Zendy; Aaron T. Gerds | Zendy; Rob M. Dean | Zendy; Brian T. Hill | Zendy; Brad Pohlman | Zendy; Deepa Jagadeesh | Zendy; Faiz Anwer | Zendy; Navneet S. Majhail | Zendy

Open Access

Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era

Author(s) -

Sanghee Hong,

Lisa Rybicki,

Donna Corrigan,

Betty K. Hamilton,

Ronald Sobecks,

Matt Kalaycio,

Aaron T. Gerds,

Rob M. Dean,

Brian T. Hill,

Brad Pohlman,

Deepa Jagadeesh,

Faiz Anwer,

Navneet S. Majhail

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.11.006

Subject(s) - medicine , hazard ratio , transplantation , myelodysplastic syndromes , myeloid leukemia , hematopoietic stem cell transplantation , oncology , leukemia , surgery , confidence interval , bone marrow

Relapse is the most common cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT). No standard of care exists, and a wide range of treatments are used for post-alloHCT relapse. In the recent era, several novel therapies including targeted agents are available for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research